Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
BörsenkürzelASRT
Name des UnternehmensAssertio Holdings Inc
IPO-datumFeb 12, 1997
CEOReisenauer (Mark L)
Anzahl der mitarbeiter58
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 12
Addresse100 S. Saunders Road
StadtLAKE FOREST
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl60045
Telefon12244197106
Websitehttps://www.assertiotx.com/
BörsenkürzelASRT
IPO-datumFeb 12, 1997
CEOReisenauer (Mark L)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten